DexCom, Inc. Reports Second Quarter 2017 Financial Results

Go back to DexCom, Inc. Reports Second Quarter 2017 Financial Results

DexCom (DXCM) PT Lowered to $92 at Oppenheimer Following 2Q

August 2, 2017 9:36 AM EDT

Oppenheimer lowered its price target on DexCom (NASDAQ: DXCM) to $92.00 (from $98.00) while maintaining a Outperform rating. 2Q17 revenue of $170.6M was ahead of the consensus estimate of $166.6M. The beat was both in the US and international. US sales were ~$140.8M, above... More

DexCom (DXCM) Tops Q2 EPS by 5c, Names CFO

August 1, 2017 4:32 PM EDT

DexCom (NASDAQ: DXCM) reported Q2 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $170.6 million versus the consensus estimate of $166.3 million.

DexCom Appoints New CFO

In conjunction with its earnings release, DexCom announced that Quentin Blackford has... More